361 related articles for article (PubMed ID: 31545245)
1. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
[TBL] [Abstract][Full Text] [Related]
2. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
4. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
Wang H; Wang X; Xu L; Zhang J; Cao H
Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969
[TBL] [Abstract][Full Text] [Related]
5. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
[TBL] [Abstract][Full Text] [Related]
6. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
7. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
8. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
[TBL] [Abstract][Full Text] [Related]
9. Phospholipase Cγ1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients.
Li T; Yang Z; Li H; Zhu J; Wang Y; Tang Q; Shi Z
Lab Invest; 2022 Feb; 102(2):143-153. PubMed ID: 34697421
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
[TBL] [Abstract][Full Text] [Related]
11. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
12. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
Vergara GA; Eugenio GC; Malheiros SMF; Victor EDS; Weinlich R
J Neurooncol; 2020 May; 147(3):587-594. PubMed ID: 32222932
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
[TBL] [Abstract][Full Text] [Related]
16. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
17. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
[TBL] [Abstract][Full Text] [Related]
18. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
19. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma.
Wu C; Song H; Fu X; Li S; Jiang T
Biomed Res Int; 2020; 2020():1086792. PubMed ID: 32280672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]